Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation

Cellular Oncology (Dordrecht)
Xiqiao ZhouGuiqin Xie

Abstract

Hepatocellular carcinoma (HCC) is an aggressive malignancy. In HCC, mitogen-activated protein kinase (MAPK) signaling is overactivated. The MAPK kinase (MEK) inhibitor trametinib has been approved to treat several types of advanced cancers with a BRAF mutation. Herein, we examined whether trametinib has efficacy against HCC. The effects of trametinib on cell viability, proliferation and tumor growth were assessed in HCC-derived cell lines and mouse xenograft models. Western blot analysis and immunohistochemistry were used to identify key regulators critical for HHC cell proliferation and tumor growth. We found that trametinib dose-dependently inhibited the viability and proliferation of HCC cells. We also found that a strong suppression of MEK by trametinib downregulated the pro-survival protein MYC, but upregulated the pro-apoptotic protein BIM. This dual differential regulation of MYC and BIM was found to be accompanied by upregulation of a MYC-targeted cyclin dependent kinase inhibitor, p27kip1 (p27), and an apoptosis marker, cleaved poly (ADP ribose) polymerase 1 (PARP), indicating a concurrent modulation of cell cycle- and apoptosis-related pathways. Importantly, we found that MYC overexpression did not block increased BIM...Continue Reading

References

Mar 31, 2004·Cancer Cell·Jordi BruixJosep M Llovet
Oct 16, 2004·Liver International : Official Journal of the International Association for the Study of the Liver·Yasunori TsuboiYutaka Aoyagi
Jul 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patricia M LorussoMark B Meyer
Jun 16, 2007·Gastroenterology·Hashem B El-Serag, K Lenhard Rudolph
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Oct 29, 2008·Oncogene·B Hoffman, D A Liebermann
Feb 18, 2010·Cell Cycle·Anthony C FaberJeffrey A Engelman
Jun 24, 2010·Blood·Jose A Richter-LarreaJose A Martinez-Climent
Sep 28, 2010·Nature·Panagis FilippakopoulosJames E Bradner
Apr 27, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bert H O'NeilDaniel M Sullivan
Sep 6, 2011·Cell·Jake E DelmoreConstantine S Mitsiades
Sep 29, 2011·Proceedings of the National Academy of Sciences of the United States of America·Jennifer A MertzRobert J Sims
Oct 14, 2011·The New England Journal of Medicine·Hashem B El-Serag
Aug 4, 2012·Cell Death and Differentiation·Y Shao, A E Aplin
Apr 27, 2013·Molecular Cancer Therapeutics·Lotfi Abou-ElkacemWiltrud Lederle
Aug 26, 2014·Future Oncology·Judy W King, Paul D Nathan
Apr 28, 2016·Journal of Hepatology·Beatrice Bissig-ChoisatKarl-Dimiter Bissig
Sep 30, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yufang MaJialiang Wang
Apr 30, 2017·Oncology Letters·Sufang Yang, Guohua Liu
Sep 12, 2017·The New England Journal of Medicine·Georgina V LongJohn M Kirkwood

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
xenografts

Software Mentioned

ImageJ

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.